Exicure, Inc is an early-stage biotechnology company based in Chicago, IL, specializing in the development of nucleic acid therapies targeting ribonucleic acid against validated targets. With a mission to provide more effective treatments for patients, Exicure utilizes its SNA platform and broad nucleic acid therapeutic capabilities to address challenging diseases in innovative ways.
Driven by their commitment to patients and their caregivers, Exicure is dedicated to pioneering novel approaches in the field of biotechnology, aiming to make a significant impact on the lives of those in need. Through their cutting-edge research and development, Exicure strives to revolutionize the treatment landscape and improve patient outcomes.
Generated from the website